flow trial semaglutide kidney outcomes 2024 nejm hazard ratio Effects of With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Disease: A Prespecified Secondary Analysis Kidney Outcomes With Glucagon-Like Peptide-1

Nutrition therapy for adults with diabetes or prediabetes: a consensus report

4-7 During midlife, the decreased amount of estrogen in a womans musculoskeletal system results in loss of lean muscle mass, loss of bone density, increased risk of fracture, increased injury to tendons and ligaments, adhesive capsulitis, cartilage matrix fragility leading to osteoarthritis, musculoskeletal pain, and metabolic dysfunction

However, dermatologists clarify that these results are gradual and vary across skin types

Building sustainability into your treatment plan from the beginning of this restart dramatically increases the probability of long-term success

Early side effects like nausea or lightheadedness during the titration phase could be relevant in safety-sensitive roles, but these are temporary